Trial Profile
A Dose-Escalation Study of AL-39324 Suspension Versus Lucentis for the Treatment of Exudative Age-Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2014
Price :
$35
*
At a glance
- Drugs AL 39324 (Primary) ; Ranibizumab
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Acronyms WALTZ
- Sponsors Alcon
- 22 May 2014 New trial record